PSD-95 inhibition in neurogenerative disorders

Created on 14 Jul 2017

Avilex Pharma

Start Up


Looking for Partnership

Looking for Lead Partner

Avilex Pharma has developed an exceptionally high-affinity inhibitor of the intracellular scaffolding protein, postsynaptic density protein 95 (PSD-95), which bridges the NMDA glutamate receptor and neuronal nitric oxide synthase (nNOS). Avilex Pharma is pursuing this peptide-based compound as a potential drug candidate for the treatment of ischaemic stroke and seeks partners to evaluate these in in vitro and in vivo models of stroke and other related neurodegenerative conditions.

 Entrepreneurship and SMEs
 Start Up
 Health Care
 Biological Sciences
 Innovation & Research

Up2Europe Ads

Recommended Calls for This Idea
If you know a call that can work with this idea

recommend a call